Amplify Therapeutics ApS
CVR 43803999 · Private limited company (ApS) · Active · Low risk
Amplify Therapeutics ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 0.5% over the next 12 months, which is 0.4 times the average for Danish companies. 3 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -12.4m and a net result of DKK -3.3m. CEO: Thomas Kirkegaard Jensen.
Bankruptcy risk for Amplify Therapeutics ApS
0.4 × the average (1.41%) · higher risk than 60% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 43803999
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (3 years)
- Address
- Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 40k
- Auditor
- PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 3 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -370.0% |
| Current ratio | 939% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK 926k | DKK -5.0m | DKK -1.6m |
| Net profit | DKK -3.3m | DKK -7.2m | DKK -2.0m |
| Equity | DKK -12.4m | DKK -9.1m | DKK -1.9m |
| Total assets | DKK 3.4m | DKK 5.9m | DKK 2.6m |
| Cash | DKK 1.5m | DKK 4.2m | – |
| Short-term debt | DKK 358k | DKK 455k | – |
| Avg. employees | 5 | 3 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · PKF Munkebo Eriksen Funch, Statsautoriseret Revisions aktie selskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 69 | ||
| 1 Jan 2024 – 31 Dec 2024 | 42 | ||
| 23 Jan 2023 – 31 Dec 2023 | 78 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Thomas Kirkegaard Jensen | Current | |
| Board | Anders Vadsholt | Current | |
| Board | Thomas Kirkegaard Jensen | Current | |
| Board | Anders Mørkeberg Hinsby | Current | |
| Owner (25%) | Alpha Healthcare Investments ApS | Current | |
| Owner (33%) | Dare to Dream ApS | Current | |
| Owner (25%) | WoB Holding ApS | Current | |
| Auditor | PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab | Current | |
| Founder | Alpha Healthcare Investments ApS | Current | |
| Founder | Dare to Dream ApS | Current | |
| Founder | WoB Holding ApS | Current |
The CEOs' other companies
Thomas Kirkegaard Jensen – 4 other companies
- Aloop Therapeutics ApS Active
- Dare to Dream ApS Active
- OZ HOLDING ApS Active
- Strategic Partners A/S Active
Address history (0 moves)
| Ole Maaløes Vej 3, 2200 København N |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- H. LUNDBECK A/S Valby
- GUNNAR KJEMS ApS København K
- Tetrapharm Therapeutics ApS København S
- Tetrapharm Bioengineering ApS København S
- Luvalis Pharma ApS Vanløse
- NeuroVersis Therapeutics ApS København K
- QuantumCell ApS København K
- Vautia Therapeutics ApS København K
- Corxel Pharmaceuticals Denmark ApS København V
- Dispersome IP ApS København Ø
- Maddox Pharma Swiss ApS København S
- Gefjon Pharma ApS København N
Questions and answers about Amplify Therapeutics ApS
Has Amplify Therapeutics ApS gone bankrupt?
No, Amplify Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Amplify Therapeutics ApS?
Our model estimates a bankruptcy risk of 0.5% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.
Who is the CEO of Amplify Therapeutics ApS?
Thomas Kirkegaard Jensen is the CEO of Amplify Therapeutics ApS.
Who is the auditor of Amplify Therapeutics ApS?
Amplify Therapeutics ApS most recently used PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab.
When was Amplify Therapeutics ApS founded?
Amplify Therapeutics ApS was founded on 23 January 2023.
What is the equity of Amplify Therapeutics ApS?
Equity was DKK -12.4m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.